The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Financial details were not disclosed.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Pharmaceutical Technology

APRIL 4, 2023

The company will undertake a technology transfer and feasibility study for a drug product focused on the treatment of IPF at its centre of cell and gene expertise in Milan, Italy. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy Gene Drug Delivery Medicine 130

Pharmaceutical Technology

APRIL 21, 2023

When combined with mRNA therapeutic molecules developed by LG Chem, the pre-made drug delivery formulation helps to simplify and improve the combination process. This is expected to shorten the development time of new drugs and to support personalised treatments.

Development 130

Development Gene Therapy Drug Delivery Gene 130

BioSpace

NOVEMBER 17, 2022

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

Gene Therapy 43

Gene Therapy Gene Gene Editing Medicine 43

Drug Discovery World

JUNE 22, 2023

“This is part of our long-term business strategy of leveraging exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”. The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

pharmaphorum

JULY 15, 2022

SAE Media Group’s 5th Annual Ophthalmic Drugs Conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing good clinical trial data. Drug delivery will also be an important aspect of the agenda, with advancements in novel technologies. And many more!

Gene Therapy 52

Gene Therapy Drugs Drug Delivery Clinical Trials 52

BioPharma Reporter

MAY 4, 2022

CPhI North America 2022 host city Philadelphia is set to become one of the worldâs biggest cell and gene therapy manufacturing hubs. But itâs just one of many centers of innovation that are helping drive the US pharma and biopharma industry.

Gene Therapy 98

Gene Therapy Gene Manufacturing Drug Delivery 98

Drug Discovery World

JANUARY 17, 2023

Limitations of AAV gene therapy . They will lead research into using LNPs to deliver a gene editing tool that could delete bad genes in the photoreceptor cells and replace them with correctly functioning genes. . Sahay and Ryals have received a $3.2

Gene Editing 98

Gene Editing Gene Gene Therapy Genetics 98

Pharmaceutical Technology

NOVEMBER 21, 2022

Additionally, the wide-ranging expertise of RVAC in mRNA, vaccine and drug delivery technologies, and its capabilities in research and development (R&D), biopharmaceutical manufacturing, clinical development and marketing is leveraged under the partnership. “We

Manufacturing 130

Manufacturing Medicine Vaccination Vaccine 130

pharmaphorum

APRIL 28, 2022

Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue. The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery.

RNA 52

RNA Drug Delivery Engineer Gene Therapy 52

Drug Discovery World

APRIL 3, 2023

As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

pharmaphorum

APRIL 29, 2021

Uncover advances in CNS gene therapy , new generation vectors for intravenous delivery, and the challenges of scaling up for CNS delivery beyond highly specialized centers. The high concentration of scientists who face similar challenges makes this Summit so essential to the development of the field.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

pharmaphorum

NOVEMBER 7, 2022

The conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing great clinical trial data. There will also be a specific focus on drug delivery along with advancements in novel technologies. The conference is co-chaired by Mitchell A.

Drugs 52

Drugs Clinical Trials Clinical Trials Gene Therapy 52

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

APRIL 29, 2024

Dr Andrew Lewis, Chief Scientific Officer; Kieron Hall, Chief Marketing Officer; and Eric Bironneau, Chief Business Officer, Quotient Sciences: Lewis has held various scientific leadership positions at Quotient and was previously Director of Novel Drug Delivery Technologies at Ipsen.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

FEBRUARY 5, 2024

This is EXO Biologics’ lead MSC-based exosome candidate for prevention of Bronchopulmonary Dysplasia (BPD) in preterm newborns. “The potential of exosomes continues to be demonstrated across the cell and gene therapy sector.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Gene Therapy 52

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

Roots Analysis

SEPTEMBER 22, 2023

These innovative instruments combine precision, convenience, and patient-centered design to revolutionize drug delivery. These devices are equipped with advanced features like programmable dosing, connectivity to mobile apps, and safety mechanisms to ensure accurate and controlled drug delivery.

Drug Delivery 40

Drug Delivery Marketing Insulin Manufacturing 40

Drug Discovery World

NOVEMBER 30, 2022

The companies hope to meet the demand for a large-scale, high-efficiency purification technology that overcomes critical issues associated with the production of clinical-quality exosomes as delivery vehicles for gene-based therapeutics. .

Production 52

Production Immune Response RNA Gene 52

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Our Social Media Platform.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

The Pharma Data

MAY 5, 2021

FDA approves 100th monoclonal antibody product ( Nature Reviews Drug Discovery ). Affinia Therapeutics raises $110 million for gene therapy treatments ( STAT ). Startup sets out to tackle the gene therapy manufacturing crisis ( Endpoints ). Medtech. Medtech.

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

pharmaphorum

JUNE 29, 2022

Among launches resilient for these reasons were Tepezza, an orphan thyroid eye disease medication in the US, Zolgensma, a gene therapy for Spinal Muscular atrophy in Germany, and more recently Evrysdi, an oral agent for the same condition. Orphan drugs launch challenges.

Doctors 57

Doctors Doctor Sales Medicine 57

The Pharma Data

JUNE 26, 2021

About Roche in Ophthalmology Roche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies. Our early stage pipeline includes gene therapies and treatments for geographic atrophy and other vision-threatening diseases, including rare and inherited conditions.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

Delveinsight

FEBRUARY 14, 2021

The health regulatory agencies all over have issued several guidelines, released strategies, and amended regulations to expedite the drug delivery process in the rare disease market landscape.

Marketing 52

Marketing Clinical Trials Clinical Trials Trials 52

The Pharma Data

MAY 15, 2023

Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

Drug Discovery World

NOVEMBER 9, 2023

The following presentations will follow: Mercedes Márquez Martínez, PhD, Technical Coordinator & Acting Scientific Director, Protein Production Platform (PPP) – Nanbiosis, Autonomous, University of Barcelona (UAB), on: ‘Host comparative production of recombinant proteins for assembling as nano- and micro-scale materials for drug delivery’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

APRIL 12, 2023

Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients.

Antibody 40

Antibody In-Vitro Development Trials 40